Content
Whatever it is, Hers can help
If you’ve ever considered taking an antidepressant, you know it's common to have a lot of questions. Will you be able to tell if it’s working? And if it does work, how long will you need to take it? Many people worry about antidepressant side effects. Others, who’ve heard stories of antidepressant withdrawal from friends or family, worry about the effects of stopping the medication.
Content
A new study might offer a bit of reassurance to this last group. Researchers found that antidepressant withdrawal, or antidepressant discontinuation syndrome, isn’t as common as once believed.
In the new meta-analysis, researchers reviewed studies that included more than 22,000 people taking either an antidepressant or a placebo. They found that only about 15 percent of patients (about 1 in 6) reported unpleasant symptoms after discontinuing these medications. Previous estimates had put that number closer to 50 percent.
Among those who did experience symptoms, they typically included dizziness, headache, nausea, insomnia, and irritability.
The likelihood that someone would experience discontinuation symptoms varied depending on the kind of antidepressant they took. Of the medications studied, those with the highest rates of discontinuation symptoms included imipramine (Tofranil), desvenlafaxine (Pristiq, Khedezla), and venlafaxine (Effexor, others). These drugs belong to a class of medications called serotonin-norepinephrine reuptake inhibitors (SNRIs).
According to the study, the antidepressants with the lowest likelihood of discontinuation symptoms include fluoxetine (Prozac) and sertraline (Zoloft). Fluoxetine and sertraline are both selective serotonin reuptake inhibitors (SSRIs).
It’s important to note that when we talk about “antidepressant withdrawal,” we’re not implying that people get addicted to antidepressants. Dr. Daniel Z. Lieberman, senior vice president of mental health at Hims & Hers, explains that there’s a difference between discontinuation symptoms and withdrawal symptoms.
“The essence of addiction that you see in withdrawal is an overpowering desire to take the drug again — and it’s not just to make the withdrawal symptoms go away,” says Dr. Lieberman, who serves as a clinical professor of psychiatry and behavioral sciences at George Washington University. “With antidepressant discontinuation, you get symptoms, and they can be very uncomfortable, they can be quite severe, but there's no craving.”
So, what actually causes discontinuation symptoms? It has to do with the time it takes for your brain to get used to living without the medication.
Look at when someone first starts taking an SSRI, says Dr. Lieberman. “The first few days, the first few weeks, you don't feel any effects. It's only two, four, maybe even eight weeks later that you're feeling better.”
“It’s the body’s adaptation to the drug,” says Dr. Lieberman, “that’s what leads to improvement.”
Discontinuation syndrome happens when this process occurs in reverse.
It’s a shock to the system, says Dr. Lieberman. “When an adapted body or an adapted brain no longer has the thing it’s adapted to.”
Discontinuation symptoms, if they do occur, tend to appear about 1 to 10 days after stopping the medication. Symptoms can range from mild to severe. This can be problematic, especially when it delays the process of switching to a different antidepressant.
According to the new study, only about 3 percent of people report severe symptoms after discontinuing antidepressants. But, some critics have pointed to the limitations of the research, noting that it may not fully account for the experiences of long-term users. The average length of time that patients in the study were taking antidepressants was 25 weeks.
As two London researchers recently argued, long-term antidepressant use is increasingly common, and these are the folks who may be most at risk of experiencing symptoms upon discontinuation. In the U.K., more than a quarter of all patients on antidepressants have been taking them for at least five years. In the U.S., more than 60 percent of people taking an antidepressant have been taking it for two years or longer.
Debate about the terms, severity, and incidence of antidepressant withdrawal isn’t new — the London researchers echo earlier work, arguing that many clinicians underestimate the likelihood and intensity of discontinuation symptoms.
Most clinicians and researchers agree that tapering is the best way to reduce your risk of discontinuation symptoms. Medication tapering is the process of gradually reducing a medication so the body has time to adapt. This process should always be done with the guidance of a medical professional.
Unfortunately, antidepressant tapering isn’t always as simple as it should be. It can be difficult when the medication is only available in a limited range of doses, and patients have to cut their pills in half or in quarters.
In many cases, says Dr. Lieberman, “The slower you taper, the more mild the symptoms are going to be.”
But this may not be necessary for everyone, he explains. According to Dr. Lieberman, the most important part of any mental health treatment plan is that it be individualized.
This is one area where compounding pharmacies, like the one Hims & Hers works with, may be able to help. With personalized mental health care, clinicians are able to offer solutions that you can’t find at mainstream retail pharmacies.
Hims & Hers has strict sourcing guidelines to ensure our content is accurate and current. We rely on peer-reviewed studies, academic research institutions, and medical associations. We strive to use primary sources and refrain from using tertiary references. See a mistake? Let us know at [email protected]!
This article is for informational purposes only and does not constitute medical advice. The information contained herein is not a substitute for and should never be relied upon for professional medical advice. Always talk to your doctor about the risks and benefits of any treatment. Learn more about our editorial standards here.
Doctor of Medicine - New York University Grossman School of Medicine, 1992
Bachelor of Arts - St. John’s College, 1985
Internship & Residency - New York University Grossman School of Medicine, 1996
District of Columbia, 1996
Maryland, 2022
Virginia, 2022
American Board of Psychiatry and Neurology, Psychiatry, 1997
American Board of Psychiatry and Neurology, Addiction Psychiatry, 1998
Stanford Online, AI in Healthcare Specialization Certificate, 2025
Stanford Online, Machine Learning Specialization Certificate, 2024
Mental Health
33
Professor and Vice Chair - Department of Psychiatry and Behavioral Sciences, George Washington University, 1996–2022
Title: A neurotransmitter approach to the trolley problem
Published in: OBM Neurobiology
Date: 2019
URL: https://www.lidsen.com/journals/neurobiology/neurobiology-03-02-030
Title: An automated internet application to help patients with bipolar disorder track social rhythm stabilization
Published in: Psychiatric Services
Date: 2011
URL: https://psychiatryonline.org/doi/10.1176/ps.62.11.pss6211_1267
Title: Enhancing adherence to mood charting with an online version of the NIMH Life Chart
Published in: Annals of General Psychiatry
Date: 2010
URL: https://annals-general-psychiatry.biomedcentral.com/articles/10.1186/1744-859X-9-S1-S11
Title: The role of gender in single versus married patients with bipolar disorder
Published in: Comprehensive Psychiatry
Date: 2010
URL: https://www.sciencedirect.com/science/article/abs/pii/S0010440X0900128X
Title: Evaluation of the stability and validity of participant samples recruited over the Internet
Published in: CyberPsychology and Behavior
Date: 2008
Title: Pathways to change: The effect of a Web application on treatment interest
Published in: The American Journal on Addictions
Date: 2008
URL: https://onlinelibrary.wiley.com/doi/10.1080/10550490802138525
Washington Post, Why do passengers freak out on airplanes? Science might have the answer.
Associated Press, MillerCoors Tapping Into Millenials
The Washington Post, Holiday drinking can be hard on your health, but you can take precautions
Le Figaro (France), Daniel Z. Lieberman: «La dopamine nous pousse à acheter en nous promettant le bonheur» (Daniel Z. Lieberman: “Dopamine drives us to buy by promising us happiness”)
Men’s Health (Spain), Cómo la dopamina influye en nuestro cerebro y determina nuestra vida (How dopamine influences our brain and determines our lives).
CNBC, The psychological reason it’s so hard to work today after the riot — and how to cope
Business Insider, The reason why we self-sabotage is because our brains are wired to resist the things we want most in life
U.S. News & World Report, How Your Secrets Can Damage and Maybe Even Kill You
I practice medicine because I believe that mental health is the foundation of a meaningful life. When people suffer psychologically, it touches every part of their existence—from relationships to work to the simple ability to feel joy. Because it can be so difficult for people who are suffering to find good mental health care, my mission has been to expand access through technology, so that no one is left behind.
I like to write in my spare time. I’ve written two nonfiction titles, Spellbound: Modern Science, Ancient Magic, and the Hidden Potential of the Unconscious Mind and the international bestseller, The Molecule of More: How a Single Chemical in Your Brain Drives Love, Sex, and Creativity--and Will Determine the Fate of the Human Race
danielzlieberman.com